01 December 2024 : Clinical Research
Rituximab use in Rheumatoid Arthritis: A Seven-Year Retrospective Study of 52 Patients at a Saudi Arabian Hospital
Sumayah Sulaiman Bafana1BCE, Fahidah Alenzi
2EFG*, Ibrahim Almaghlouth1AD, Eman Alqurtas 1AD, Mohammed K. Bedaiwi1ABD, Haya M. M. Almalag 3AD, Mohammed A. Omair 1ACDEF
DOI: 10.12659/MSM.946178
Med Sci Monit 2024; 30:e946178
Table 3 Rituximab profiles of the patients.
| Reason for RTX initiation (n (%)) | |
|---|---|
| Primary failure | 21 (40) |
| Secondary failure | 7 (13) |
| Development of adverse events | 9 (17) |
| Presence of malignancy | 1 (1.9) |
| Presence of ILD | 1 (1.9) |
| No specific reason | 13 (25) |
| RTX discontinuation | 7 (13.46) |
| Adverse events | 2 (28.56) |
| Treatment failure | 3 (42.85) |
| Remission | 1 (14.28) |
| Death | 1 (14.28) |
| RTX – Rituximab; ILD – interstitial lung disease. | |